# Oxaliplatin

Source: https://onco.cc/drugs/oxaliplatin/  
OnCo record `oxaliplatin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The platinum drug that works in bowel cancer where cisplatin does not, the 'OX' in FOLFOX and CAPOX; its cost is nerve damage in hands and feet.

## Summary

Approved EU 1996, US 2002 (second line, then adjuvant colon after MOSAIC 2004). FOLFOX/CAPOX backbone in colorectal, gastro-oesophageal (FLOT), pancreatic (FOLFIRINOX), biliary (second line), appendiceal and neuroendocrine (CAPTEM alternatives). IDEA (2018) showed 3 months of CAPOX suffices for low-risk stage III colon cancer, limiting neuropathy.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill; generic; who-essential
- Brand: Eloxatin
- Modality: Third-generation platinum (DACH-platinum)
- Mechanism: Forms bulky DACH-platinum DNA adducts poorly recognised by mismatch repair, giving activity in cisplatin-resistant colorectal cancer; causes acute cold-triggered and cumulative sensory neuropathy.
- Approvals: EU 1996: Metastatic colorectal cancer; US 2002: Metastatic colorectal cancer with 5-FU/LV; US 2004: Adjuvant stage III colon cancer

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Oxaliplatin
- MOSAIC (NEJM 2004): https://doi.org/10.1056/NEJMoa032709
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=oxaliplatin

## Connected records

- cancers: [Appendiceal cancer and pseudomyxoma peritonei](https://onco.cc/cancers/appendiceal/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Extranodal NK/T-cell lymphoma](https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Mucinous ovarian cancer](https://onco.cc/cancers/mucinous-ovarian-cancer/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic acinar cell carcinoma](https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- technologies: [Acupuncture for chemotherapy-induced neuropathy](https://onco.cc/technologies/acupuncture-chemotherapy-neuropathy/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Glutamine for mucositis and neuropathy](https://onco.cc/technologies/glutamine-mucositis-neuropathy/), [HIPEC perfusion pumps and PIPAC nebulisers](https://onco.cc/technologies/hipec-pipac-devices/), [Nerve damage from chemotherapy: what recovers, and what helps](https://onco.cc/technologies/cipn-recovery-and-treatment/), [Platinum agents](https://onco.cc/technologies/platinum/), [Scrambler therapy (Calmare) for chemotherapy nerve pain](https://onco.cc/technologies/scrambler-therapy/), [Small-molecule API synthesis](https://onco.cc/technologies/small-molecule-api-synthesis/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)
- trials: [A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma](https://onco.cc/trials/nct07791758/), [A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06741644/), [A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.](https://onco.cc/trials/nct07283367/), [A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]](https://onco.cc/trials/nct07390383/), [A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.](https://onco.cc/trials/nct07679399/), [A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies](https://onco.cc/trials/nct05329766/), [A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs](https://onco.cc/trials/nct06423170/), [A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.](https://onco.cc/trials/nct06654947/), [A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies](https://onco.cc/trials/nct07415031/), [A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)](https://onco.cc/trials/nct07582315/), [A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct05859750/), [A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer](https://onco.cc/trials/nct06662786/), [A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors](https://onco.cc/trials/nct07730021/), [A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure](https://onco.cc/trials/nct07606599/), [A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)](https://onco.cc/trials/nct05849480/), [A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.](https://onco.cc/trials/nct07315750/), [A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer](https://onco.cc/trials/nct05980481/), [A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer](https://onco.cc/trials/nct03505320/), [A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer](https://onco.cc/trials/nct06901531/), [A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States](https://onco.cc/trials/nct07554521/), [A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)](https://onco.cc/trials/nct05144854/), [A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)](https://onco.cc/trials/nct06256328/), [ABC-06](https://onco.cc/trials/abc-06/), [AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer](https://onco.cc/trials/nct06951503/), [Alliance N0147](https://onco.cc/trials/n0147/), [Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment](https://onco.cc/trials/nct06662877/), [Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial](https://onco.cc/trials/nct05701436/), [Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial](https://onco.cc/trials/nct05766605/), [BALLAD](https://onco.cc/trials/ballad/), [Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer](https://onco.cc/trials/nct05451290/), [CAO/ARO/AIO-12](https://onco.cc/trials/cao-aro-aio-12/), [CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C](https://onco.cc/trials/nct07383285/), [Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer](https://onco.cc/trials/nct00399035/), [CLASSIC](https://onco.cc/trials/classic/), [Clinical Studies for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06825494/), [Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer](https://onco.cc/trials/nct07522151/), [Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct06854445/), [CLOCC](https://onco.cc/trials/clocc/), [COLOPEC](https://onco.cc/trials/colopec/), [Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07151872/), [ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations](https://onco.cc/trials/combomatch-binimetinib-folfox/), [CONKO-003 (OFF)](https://onco.cc/trials/conko-003/), [Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)](https://onco.cc/trials/nct06502080/), [Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)](https://onco.cc/trials/nct05771480/), [DYNAMIC-III](https://onco.cc/trials/dynamic-iii/), [EORTC 40983](https://onco.cc/trials/eortc-40983/), [ESOPEC](https://onco.cc/trials/esopec/), [Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL](https://onco.cc/trials/nct06806033/), [Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer](https://onco.cc/trials/nct07056777/), [FLOT4-AIO](https://onco.cc/trials/flot4/), [FOxTROT](https://onco.cc/trials/foxtrot/), [FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM](https://onco.cc/trials/nct03678428/), [GETUG 13](https://onco.cc/trials/getug-13/), [Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma](https://onco.cc/trials/nct03364530/), [IDEA collaboration](https://onco.cc/trials/idea-collaboration/), [Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer](https://onco.cc/trials/nct07263360/), [Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07238283/), [KEYNOTE-811](https://onco.cc/trials/keynote-811/), [Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE](https://onco.cc/trials/nct04919226/), [mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line](https://onco.cc/trials/nct07062536/), [MOSAIC](https://onco.cc/trials/mosaic/), [MOUNTAINEER](https://onco.cc/trials/mountaineer/), [MOUNTAINEER-03](https://onco.cc/trials/mountaineer-03/), [MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06840665/), [MRC COIN](https://onco.cc/trials/coin/), [New EPOC](https://onco.cc/trials/new-epoc/), [NORPACT-1](https://onco.cc/trials/norpact-1/), [OPUS](https://onco.cc/trials/opus/), [ORIENT-16](https://onco.cc/trials/orient-16/), [Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer](https://onco.cc/trials/nct00268463/), [Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06230471/), [Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.](https://onco.cc/trials/nct06155383/), [PETACC-8](https://onco.cc/trials/petacc-8/), [Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer](https://onco.cc/trials/nct05671822/), [Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)](https://onco.cc/trials/nct04379596/), [Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors](https://onco.cc/trials/nct05945823/), [Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer](https://onco.cc/trials/nct06852287/), [POLARGO](https://onco.cc/trials/polargo/), [Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study](https://onco.cc/trials/nct07729917/), [PRIME](https://onco.cc/trials/prime/), [PRODIGE 23](https://onco.cc/trials/prodige-23/), [PRODIGE 4 / ACCORD 11](https://onco.cc/trials/prodige-4-accord-11/), [PRODIGE 7](https://onco.cc/trials/prodige-7/), [Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC](https://onco.cc/trials/nct03478488/), [PROPHYLOCHIP-PRODIGE 15](https://onco.cc/trials/prophylochip/), [QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors](https://onco.cc/trials/nct06892925/), [RAPIDO](https://onco.cc/trials/rapido/), [RUGB](https://onco.cc/trials/rugb/), [Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06771622/), [SCOT](https://onco.cc/trials/scot/), [Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07025174/), [SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05300269/), [Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct07831993/), [Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2](https://onco.cc/trials/nct07431281/), [SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients](https://onco.cc/trials/nct03448549/), [SPOTLIGHT & GLOW](https://onco.cc/trials/spotlight-glow/), [STELLAR (rectal cancer)](https://onco.cc/trials/stellar-rectal/), [Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)](https://onco.cc/trials/nct05239741/), [Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer](https://onco.cc/trials/nct06247956/), [Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer](https://onco.cc/trials/nct04725994/), [Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)](https://onco.cc/trials/nct06469944/), [Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)](https://onco.cc/trials/nct06780111/), [Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA](https://onco.cc/trials/nct04183712/), [Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial](https://onco.cc/trials/nct05863195/), [TOSCA](https://onco.cc/trials/tosca/), [TRIBE](https://onco.cc/trials/tribe/), [Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct07146646/), [Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer](https://onco.cc/trials/nct07267078/)
- key papers: [CLASSIC 5-year follow-up: adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy](https://onco.cc/key-papers/paper-classic-5-year-follow-up-noh-lancet-oncol-2014/), [CLASSIC: adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy](https://onco.cc/key-papers/paper-classic-adjuvant-capox-gastric-bang-lancet-2012/), [Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)](https://onco.cc/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/), [Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7)](https://onco.cc/key-papers/paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021/), [Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)](https://onco.cc/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/), [FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma](https://onco.cc/key-papers/paper-flot4-lancet-2019/), [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of TRIBE](https://onco.cc/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/), [Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23)](https://onco.cc/key-papers/paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021/), [Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)](https://onco.cc/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/), [Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)](https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/), [Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression](https://onco.cc/key-papers/paper-crane-smad4-progression-pattern-locally-advanced-jco-2011/), [Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma: results from the phase III, randomized POLARGO trial](https://onco.cc/key-papers/paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026/), [Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)](https://onco.cc/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/), [Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy in locally advanced rectal cancer (RAPIDO)](https://onco.cc/key-papers/paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021/)
- people: [Rachel Kerr](https://onco.cc/people/rachel-kerr/)
- roadmaps: [Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs](https://onco.cc/roadmaps/chemotherapy-roadmap/), [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/)
- ideas: [Find peritoneal spread while it is still small, and run complete cytoreduction through networks rather than adding heated chemotherapy](https://onco.cc/ideas/idea-crc-peritoneal-disease-found-early-and-treated-in-networks/)
- drugs: [FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)](https://onco.cc/drugs/folfoxiri/)
- terms: [FLOT regimen (perioperative chemotherapy for gastric cancer)](https://onco.cc/terms/flot-term/), [FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX](https://onco.cc/terms/folfox-family/), [Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies](https://onco.cc/terms/chemotherapy-side-effects-colorectal/), [Peripheral neuropathy (chemotherapy-induced)](https://onco.cc/terms/peripheral-neuropathy/), [The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest](https://onco.cc/terms/lymphoma-tx-regimen-alphabet/)

---
JSON: https://onco.cc/api/v1/entities/oxaliplatin.json